Crews Bank & Trust Takes Position in Boston Scientific Co. (NYSE:BSX)

Crews Bank & Trust acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 951 shares of the medical equipment provider’s stock, valued at approximately $85,000.

Several other institutional investors also recently modified their holdings of BSX. DMC Group LLC grew its stake in Boston Scientific by 13.6% in the 4th quarter. DMC Group LLC now owns 7,899 shares of the medical equipment provider’s stock worth $706,000 after buying an additional 947 shares in the last quarter. Highland Capital Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $4,887,000. Foster Victor Wealth Advisors LLC grew its position in Boston Scientific by 0.8% in the fourth quarter. Foster Victor Wealth Advisors LLC now owns 196,112 shares of the medical equipment provider’s stock worth $19,348,000 after acquiring an additional 1,517 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in Boston Scientific by 13.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 1,922,301 shares of the medical equipment provider’s stock valued at $171,700,000 after acquiring an additional 224,280 shares during the last quarter. Finally, Sumitomo Life Insurance Co. raised its position in Boston Scientific by 11.3% during the fourth quarter. Sumitomo Life Insurance Co. now owns 99,858 shares of the medical equipment provider’s stock valued at $8,919,000 after purchasing an additional 10,098 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

BSX stock opened at $102.40 on Friday. The firm has a 50-day moving average of $93.22 and a 200 day moving average of $86.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market cap of $150.92 billion, a P/E ratio of 84.63, a PEG ratio of 2.69 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $62.63 and a 1 year high of $104.25.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BSX. Royal Bank of Canada upped their price objective on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Wells Fargo & Company upped their target price on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein lifted their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. Finally, Bank of America lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $98.35.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.